Shen, Chen & Gao (2023) constructed a mesenchymal stem cell-relevant model for assessing prognosis and drug sensitivity in STAD patients via scRNA-seq approach. Similarly, through integrating scRNA-seq with bulk data, CXCR4 on tumor-infiltrating B cells showed inferior survival outcomes and was considered as a therapeutic targets for STAD (Su et al., 2023). However, macrophage relevant study based on scRNA-seq method in LUAD is rare, only one M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of STAD was published (Gao et al., 2023). Here, CXCR4 is linked to gastric adenocarcinoma.